-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)
-
-
-
-
-
-
-
Madrigal Pharmaceuticals (MDGL) PT Lowered to $542 at BofA Securities
-
-
-
-
-
-
-
Bernstein on US Pharma and Biotech: Who might buy whom?
-
-
-
-
-
-
-
Madrigal licenses six siRNA programs for MASH treatment development
-
-
-
-
-
-
-
Piper Sandler on Biotechnology: 'What Commercial Names to Own in 2026?'
-
-
-
-
-
-
-
Madrigal Pharmaceuticals (MDGL) PT Raised to $527 at Citizens on Redziffra Sales
-
-
-
-
-
-
-
Madrigal Pharmaceuticals (MDGL) PT Raised to $590 at Oppenheimer
-
480,450 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


